

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 5
 ICB commissioned 0
 Non-ICB commissioned 2
 Not applicable 3
 ICB commissioned and approved 0
 Average days to compliance 0

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [TA963]	Recommended	03/04/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma [TA964]	Recommended	10/04/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) [TA966]	Terminated appraisal	24/04/2024	TA					N/A	Terminated appraisal
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA968]	Terminated appraisal	25/04/2024	TA					N/A	Terminated appraisal
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) [TA969]	Terminated appraisal	30/04/2024	TA					N/A	Terminated appraisal